Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192381 | PMC |
| http://dx.doi.org/10.4103/aian.aian_990_24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Advancing 131I-MIBG Therapy-New Horizons in Treating Malignant Pheochromocytoma and Paraganglioma].
Gan To Kagaku Ryoho
July 2025
Dept. of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine.
131I-MIBG radionuclide therapy for the recurrence case of phaeochromocytoma and paraganglioma has been used in Europe from the 1980s, and in Japan from the 1990s by patient's expense. 131I-MIBG therapy for malignant phaeochromocytoma and paraganglioma became the insurance adaptation in Japan in 2022, however there are not enough number of the facilities that can enforce this treatment now. Because radioactivity is given by oneself after the treatment, the patient is hospitalized in the lead cover room that is a radiation therapy sickroom.
View Article and Find Full Text PDF[F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET.
Eur J Nucl Med Mol Imaging
July 2025
Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang Province, China.
Purpose: [F]-meta-fluorobenzylguanidine ([F]MFBG) and somatostatin receptor (SSTR)-targeted PET tracers have both been proposed for imaging neuroblastoma, however, their respective clinical roles remain unclear. This prospective study compared [F]MFBG PET with SSTR-targeted PET, using either [Ga]Ga-DOTATATE or [F]AlF-NOTA-octreotide([F]-OC), to evaluate diagnostic performance and potential clinical impact in neuroblastoma.
Methods: Sixteen patients (median age 5.
Potentially fatal crisis after Lu-DOTATATE therapy for paraganglioma: a case report with review of literature.
Endocr J
July 2025
Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan.
Pheochromocytoma/paraganglioma (PPGL) is a rare neuroendocrine tumor with metastatic potential. Peptide receptor radionuclide therapy with Lu-DOTATATE, a radiolabeled somatostatin analog, has been used for the treatment of somatostatin receptor-positive PPGLs and has shown promising efficacy and generally mild toxicity. However, rare instances of fatal crises following treatment have been reported.
View Article and Find Full Text PDFDosimetry-Guided [I]MIBG Therapy in a Hemodialysis-Dependent Paraganglioma Patient.
J Nucl Med
September 2025
Department of Diagnostic Radiology, OHSU, Portland, Oregon; and.
High specific-activity I-metaiodobenzylguanidine ([I]MIBG) therapy is approved for patients with pheochromocytoma or paraganglioma. As [I]MIBG is not effectively cleared through dialysis, the 2008 European Association of Nuclear Medicine guidelines list renal insufficiency requiring dialysis as a contraindication for [I]MIBG treatment. We describe the clinical and dosimetry findings of a hemodialysis-dependent patient with metastatic paraganglioma who was treated with [I]MIBG.
View Article and Find Full Text PDFRelease of HMGB1 from human-derived cancer and normal cells by internal targeted radiotherapy with 131I-meta-iodobenzylguanidine.
J Radiat Res
July 2025
Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.
The rare abscopal effect in radiotherapy is thought to result from immune-activating damage-associated molecular patterns, such as high mobility group box-1 protein (HMGB1), released from cancer cells. While external irradiation of cancer cells increases HMGB1 release, it remains unclear whether internal radiotherapy with 131I-meta-iodobenzylguanidine (131I-MIBG) induces similar effects. This study aimed to determine if HMGB1 is released from human-derived cancer and normal cells after 131I-MIBG administration.
View Article and Find Full Text PDF